0.0000.000æéå€ååŒÂ  (ET)
--æäŸ¡ç·é¡
--çŽè¿12ã¶æPER
äž»èŠããŒã¿
--å§å€
0.000é«å€
0.00åºæ¥é«
--çŽè¿12ã¶æPER
--äºæ³PER
--çŽè¿12ã¶æé
åœ
--売買å転ç
--忥çµå€
0.000å®å€
0.00売買代é
--æ ªäŸ¡åçç
--PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
--çŽè¿12ã¶æé
åœå©åã
--ç·è³ç£å©çç
--52é±é«å€
--åºæ¥é«æ¯ç%
--çŽå©ç
--æ ªåŒæ°
--1æ ªåœããå©çïŒEPSïŒ
--ããŒã¿å€
--èªå·±è³æ¬å©çç
--52é±å®å€
--æ¯ãå¹
--ç²å©çç
--æäŸ¡ç·é¡
--ãªã¹ã¯ãªã¿ãŒã³
--ãªã¹ã¯ç
Sinovac Biotech Ltd ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
ææšî
ææš
売ã(0)
äžç«(4)
è²·ã(0)
ç§»åå¹³å
売ã(0)
äžç«(6)
è²·ã(0)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Sinovac Biotech Ltdã®äŒæ¥æ
å ±î
Sinovac Biotech Ltd (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, hand foot and mouth disease (HFMD), seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine.
äŒæ¥ã³ãŒãSVA
äŒæ¥åSinovac Biotech Ltd
æé«çµå¶è²¬ä»»è
ãCEOãYin (Weidong)
ãŠã§ããµã€ãhttp://www.sinovac.com/
æ ªäž»çµ±èšî
ãããã質å
Sinovac Biotech Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îSinovac Biotech Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯SVAã§ãã
Sinovac Biotech Ltd (SVA) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îSinovac Biotech LtdïŒSVAïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.83ã§ãã